Cisplatin and Flavopiridol in Treating Patients With Advanced Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Status:	Archived
Conditions:	Ovarian Cancer, Cancer, Cancer
Therapuetic Areas:	Oncology
Healthy:	No
Age Range:	Any
Updated:	7/1/2011

Phase II Trial Of Flavopiridol And Cisplatin In Advanced Epithelial Ovarian And Primary Peritoneal Carcinomas

RATIONALE: Drugs used in chemotherapy, such as cisplatin and flavopiridol, work in different
ways to stop tumor cells from dividing so they stop growing or die. Combining more than one
drug may kill more tumor cells.

PURPOSE: This phase II trial is studying how well giving cisplatin together with
flavopiridol works in treating patients with advanced ovarian epithelial cancer or primary
peritoneal cancer.

OBJECTIVES:

- Determine the response rate, time to progression, and survival in patients with
advanced ovarian epithelial or primary peritoneal cancer treated with cisplatin and
flavopiridol.

- Determine the toxicity of this regimen in these patients.

OUTLINE: This is a multicenter study. Patients are accrued to two separate groups (Group 2
closed to accrual as of 3/10/06).

- Group 1

- Patients receive cisplatin IV over 30 minutes and flavopiridol IV over 24 hours on
day 1. Courses repeat every 3 weeks in the absence of disease progression or
unacceptable toxicity.

- Group 2

- Patients receive cisplatin IV over 30 minutes and flavopiridol IV over 24 hours on
day 1. Courses repeat every 3 weeks in the absence of disease progression or
unacceptable toxicity.

Patients are followed every 3 months for up to 3 years.

PROJECTED ACCRUAL: A total of 38-79 patients (20-42 for group 1 and 18-37 for group 2
[Closed to accrual as of 3/10/06]) will be accrued for this study within 7-14 months.

We found this trial at

sites

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Baltimore, Maryland 21231

410-955-6190